Misstala 30 mg filmomhulde tablet

País: Holanda

Língua: holandês

Origem: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Ingredientes ativos:

ULIPRISTALACETAAT 30 mg/stuk

Disponível em:

Zentiva k.s. U kabelovny 130 102 37 PRAGUE 10 (TSJECHIË)

Código ATC:

G03AD02

DCI (Denominação Comum Internacional):

ULIPRISTALACETAAT 30 mg/stuk

Forma farmacêutica:

Filmomhulde tablet

Composição:

HYPROLOSE (E 463) ; HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; NATRIUMZETMEELGLYCOLAAT ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), HYPROLOSE (E 463) ; HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; NATRIUMZETMEELGLYCOLAAT ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), HYPROLOSE (E 463) ; HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; NATRIUMZETMEELGLYCOLAAT (E468) ; STEARINEZUUR (E 570) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171)

Via de administração:

Oraal gebruik

Área terapêutica:

Ulipristal

Data de autorização:

1900-01-01

Folheto informativo - Bula

Ulipristal acetate NL-H-4446_ PSUSA 01.2022 implemented 23.02.2022
C2-Internal
PACKAGE LEAFLET: INFORMATION FOR THE USER
MISSTALA 30 MG FILMOMHULDE TABLET
ulipristal acetate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your pharmacist, doctor or other
healthcare professional has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your pharmacist, doctor, or other
healthcare professional.
This includes any possible side effects not listed in this leaflet.
see section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Misstala is and what it is used for
2.
What you need to know before you take Misstala
3.
How to take Misstala
4.
Possible side effects
5.
How to store Misstala
6.
Contents of the pack and other information
- Useful information about contraception
1. WHAT MISSTALA IS AND WHAT IT IS USED FOR
Misstala is an emergency contraceptive
Misstala is a contraceptive intended to prevent pregnancy after
unprotected sex or if your
contraceptive method has failed. For example:
•
if you had sex without protection;
•
if your or your partner’s condom tore, slipped or came off, or if
you forgot to use one;
•
if you did not take your contraceptive pill as recommended.
You should take the tablet as soon as possible after sex, and within a
maximum of 5 days (120
hours).
This is because the sperm can survive up to 5 days in your body after
intercourse.
This medicine is suitable for any woman of childbearing age, including
adolescents.
You can take the tablet at any time in the menstrual cycle.
Misstala does not work if you are already pregnant.
If your menstrual period is late, there is a possibility that you may
be pregnant. When your period is
late or when you have symptoms of pregnancy (heavy breasts, morning
sickness) you should consult
a doctor or other healthcare profess

Características técnicas

Ulipristal acetate NL-H-4446_ renewal 20.6.2023
C2-Internal
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Misstala 30 mg filmomhulde tablet
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 30 mg ulipristal acetate.
Excipients with known effect:
Each tablet contains 240.0 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM
Film-coated tablet
White, round, biconvex, film-coated tablet of 9.0 – 9.2 mm diameter
embossed with
_“U30” _
on one
side.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Emergency contraception within 120 hours (5 days) of unprotected
sexual intercourse or
contraceptive failure.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The treatment consists of one tablet to be taken orally as soon as
possible, but no later than 120 hours
(5 days) after unprotected intercourse or contraceptive failure.
The tablet can be taken at any time during the menstrual cycle.
If vomiting occurs within 3 hours of the tablet intake, another tablet
should be taken.
If a woman’s menstrual period is late or in case of symptoms of
pregnancy, pregnancy should be
excluded before the tablet is administered.
Special populations
_Renal impairment _
No dose adjustment is necessary.
_ _
_Hepatic impairment _
In the absence of specific studies, no alternate dose recommendations
for ulipristal acetate can be
made.
_ _
_Severe hepatic impairment _
In the absence of specific studies, ulipristal acetate is not
recommended.
Ulipristal acetate NL-H-4446_ renewal 20.6.2023
C2-Internal
_ _
_Paediatric population _
There is no relevant use of ulipristal acetate for children of
prepubertal age in the indication
emergency contraception
_. _
Adolescents: ulipristal acetate for emergency contraception is
suitable for any woman of child
bearing age, including adolescents. No differences in safety or
efficacy have been shown compared
to adult women aged 18 and older (see section 5.1).
Method of administration
Oral use.
The tablet can be tak